Improving CPT-11 Efficacy Using Structural and Chemical Biology

利用结构生物学和化学生物学提高 CPT-11 功效

基本信息

批准号：
9326146
负责人：
Matthew R Redinbo
金额：
$ 26.39万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-09-23 至 2019-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9326146
关键词：
Acute Address Adverse effects Animals Anti-Inflammatory Agents Anti-inflammatory Antineoplastic Agents Applied Research Bacteria Basic Science Beta-glucuronidase Binding Biological Biology Camptothecin-11 Cell Death Chemicals Chemotherapy-Oncologic Procedure Colorectal Cancer Diarrhea Dose-Limiting Enteral Enzymes Epithelial Cells Glucuronic Acids Glucuronidase Inhibitor Goals Health Human In Vitro Intestines Knowledge Malignant Neoplasms Malignant neoplasm of pancreas Mammalian Cell Metagenomics Molecular Oral Pharmaceutical Chemistry Pharmaceutical Preparations Pharmacology Proteins Reagent Research Science Structural Biochemistry Structure Sugar Acids Symbiosis Testing Therapeutic Time Toxic effect Ulcer deep sequencing design enzyme activity gut microbiome gut microbiota improved improved outcome inhibitor/antagonist irinotecan microbial microbiome microbiota mouse model mutualism novel novel therapeutics public health relevance structural biology therapeutic enzyme tool

项目摘要

DESCRIPTION (provided by applicant): We are alleviating the toxicity of the anticancer drug CPT-11 by modulating components of the GI microbiome. CPT-11 is essential in treating colorectal and pancreatic cancer, but dose-limiting toxicity severely reduces its efficacy. This toxicity is caused by a bacterial enzyme in enteric microbial symbiotes. The enzyme, ß-glucuronidase, removes the inactivating glucuronic acid sugar from CPT-11's key metabolite, which reactivates the drug in the GI and produces epithelial cell death and acute diarrhea. We hypothesized that the selective, non-lethal inhibition of microbial ß-glucuronidases would alleviate this side effect. This hypothesis tested true in proof-of-concept molecular-to-animal studies conducted in the previous project period. We will now advance the project in three crucial ways. First, we will characterize the range of active ß-glucuronidases present in the GI microbiome using structural biology and biochemistry. Second, we will create differentially optimized bacterial ß-glucuronidase inhibitors via structural and chemical biology. Third, using deep-sequencing and metagenomics, we will unravel how this approach impacts the composition and activity of the GI microbiome. In summary, we seek to advance a novel paradigm - inhibiting specific microbial enzymes for therapeutic gain without harming the bacterial symbiotes essential for human health.

描述（由申请人提供）：我们正在通过调节胃肠道微生物组的成分来减轻抗癌药物 CPT-11 的毒性，这对于治疗结直肠癌和胰腺癌至关重要，但剂量限制性毒性严重降低了其疗效。毒性是由肠道微生物共生体中的细菌酶引起的，β-葡萄糖醛酸酶可去除失活的葡萄糖醛酸糖。 CPT-11 的关键代谢物会重新激活胃肠道中的药物并产生上皮细胞死亡和急性腹泻，我们发现，对微生物 β-葡萄糖醛酸酶的选择性、非致命性抑制可以减轻这种副作用。我们现在将以三个关键方式推进该项目，首先，我们将描述活性范围。其次，我们将通过结构生物学和化学生物学创建差异优化的细菌 β-葡萄糖醛酸酶抑制剂。第三，利用深度测序和宏基因组学，我们将揭示这种方法如何影响其成分。总之，我们寻求推进一种新的范例 - 抑制特定的微生物酶以获得治疗效果而不伤害细菌。对人类健康至关重要的共生体。